EUVIMEDEUVIMED entdecken
Crossref

Chrysoeriol: a natural RANKL inhibitor targeting osteoclastogenesis and ROS regulation for osteoporosis therapy

Hao Luo, Sijian Lin, Hao Lv, Wen Tan, Junlong Zhong, Jiachao Xiong, ZhiMing Liu, Qin Wu, Ming Chen, Kai Cao

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-024-03714-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Hao Luo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Orthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China. Hauptthemen laut MEDLINE: RANK Ligand, Reactive Oxygen Species, Osteoclasts, Osteoporosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Research Project of Jiangxi Provincial Department of Education, Research Project of Health Commission of Jiangxi Province, Project of Jiangxi Provincial Administration of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chrysoeriol (CHE) is a naturally occurring compound with established anti-inflammatory and anti-tumor effects. This study examines its potential role in regulating osteoclast differentiation and activity, both of which are crucial for bone remodeling. Computational docking revealed high binding affinity between CHE and RANKL, specifically at the Lys-181 residue of RANKL, suggesting potential inhibitory interactions on osteoclastogenesis. In vitro assays confirmed CHE's non-toxic profile at concentrations below 20 μM and demonstrated a dose-dependent suppression of osteoclast differentiation. Notably, CHE treatment significantly reduced TRAP activity and bone resorption capacity in a dose-dependent manner. Furthermore, CHE markedly decreased ROS production by NOX-1 expression and modulated the NRF2/KEAP1 pathway to enhance ROS clearance. The compound also showed inhibitory effects on the NF-κB and MAPK signaling pathways, which are crucial for osteoclast activation. In an ovariectomized mouse model, administration of CHE mitigated bone loss, indicating its therapeutic potential in osteoporosis. Collectively, these findings establish CHE as a promising natural therapeutic agent for treating bone disorders characterized by excessive bone resorption, underscoring the need for further clinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RANK LigandReactive Oxygen SpeciesOsteoclastsOsteoporosisOsteogenesisAnthraquinonesAnimalsMiceFemaleRAW 264.7 CellsMice, Inbred C57BLMolecular Docking SimulationOvariectomyBone ResorptionNF-kappa BCell DifferentiationHumansDose-Response Relationship, Drug

Stichwörter der Autor:innen

ChrysoeriolNFATc1OsteoclastOsteoporosisROS

Substanzen

RANK LigandReactive Oxygen SpeciesTnfsf11 protein, mouseAnthraquinonesNF-kappa B

Autor:innen und Institutionen

  • Orthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China.
  • The Rehabilitation Medicine Department, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China.
  • Orthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China. ndyfy01837@ncu.edu.cn.
  • The Key Laboratory of Spine and Spinal Cord Disease of Jiangxi Province, Nanchang, 330006, China. caokai@ncu.edu.cn.
  • Department of Orthopedics, Affiliated Rehabilitation Hospital of Nanchang University, Nanchang, 330002, China. caokai@ncu.edu.cn.

Förderung

  • Research Project of Jiangxi Provincial Department of Education
  • Research Project of Health Commission of Jiangxi Province
  • Project of Jiangxi Provincial Administration of Traditional Chinese Medicine
  • National Natural Science Foundation of China
  • Double-thousand Plan Program of Jiangxi Province
  • Clinical Cultivation Project of The First Affiliated Hospital of Nanchang University

Zitieren

APA

Luo, H., Lin, S., Lv, H., Tan, W., Zhong, J., Xiong, J., Liu, Z., Wu, Q., Chen, M., & Cao, K. (2025). Chrysoeriol: a natural RANKL inhibitor targeting osteoclastogenesis and ROS regulation for osteoporosis therapy. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03714-3

Vancouver

Luo H, Lin S, Lv H, Tan W, Zhong J, Xiong J, et al. Chrysoeriol: a natural RANKL inhibitor targeting osteoclastogenesis and ROS regulation for osteoporosis therapy. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03714-3

BibTeX
@article{Luo2025,
  author = {Luo, Hao and Lin, Sijian and Lv, Hao and Tan, Wen and Zhong, Junlong and Xiong, Jiachao and Liu, ZhiMing and Wu, Qin and Chen, Ming and Cao, Kai},
  title = {Chrysoeriol: a natural RANKL inhibitor targeting osteoclastogenesis and ROS regulation for osteoporosis therapy},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-024-03714-3}
}
Kostenlos starten →